Each film coated tablet contains: Diosmin micronized powder 90% eq. to Diosmin, USP 450 mg, Hesperidin 90% eq. to Hesperidin, USP 50 mg.
Pharmacology: DIOSPER is a phlebotonic drug and a vascular protecting agent. Its efficacy is accounted for its specific action on the principal elements of venous disease.
Venous tonic activity: DIOSPER is a phlebotonic. It reinforces venous tone by prolonging the activity of parietal noradrenaline. Thus, it decreases venous capacitance, venous distensibility and venous emptying time.
Microcirculatory activity: DIOSPER protects microcirculation by fighting the microcirculation-damaging process. It combats venous inflammation by decreasing leukocyte activation and as a consequence, by inhibiting the release of inflammatory mediators, principally free radicals and prostaglandins. Thus, it normalizes capillary permeability and strengthens capillary resistance.
DIOSPER acts on the lymphatic system. It improves lymphatic drainage by increasing lymph flow and lymph oncotic pressure. This action on the lymphatic system associated with phlebotonic and vasculoprotective effect, explains the activity of DIOSPER on CVI-associated edema.
Pharmacokinetics: In man, following the administration of the substance containing 14C Diosmin: Excretion is mainly fecal, a mean of 14% of the dose administered is excreted in the urine.
Elimination half-life is 11 hours.
The drug is extensively metabolized as evidenced by the presence of various phenol acids in the urine.
Treatment of symptoms related to venolymphatic insufficiency (heavy legs, pain, early morning restless legs).
Treatment of functional symptoms related to acute hemorrhoidal attack.
Usual dosage is 2 tablets daily in two divided doses, midday and evening at mealtimes.
Acute hemorrhoidal attack: 6 tablets per day for the first 4 days, then 4 tablets per day for 3 days.
Acute hemorrhoidal attack: Administration of this medicine is no substitute for the specific treatment of other anal disorders. The treatment must be short-term. If the symptoms do not appear rapidly, proctological examination should be performed and the treatment reviewed.
Pregnancy: Experimental studies in animals have not demonstrated any teratogenic effect in animals. Furthermore, no adverse effects have been reported to date in humans.
Breastfeeding: In the absence of data concerning excretion into breast milk, breastfeeding is not recommended during treatment.
A few cases of minor gastrointestinal and neurovegetative disorders have been reported which did not require suspension of treatment.
Store at temperatures not exceeding 30°C.
C05CA53 - diosmin, combinations ; Belongs to the class of bioflavonoids used as capillary stabilizing agents.
Sign Out
Continue with Google
Sign up with email
Already a member?
Sign in
